Title : Drug resistance-associated substitutions identified in HCV genes
link : Drug resistance-associated substitutions identified in HCV genes
Drug resistance-associated substitutions identified in HCV genes
Gastroenterology 2017
View Abstract
DOI: http://ift.tt/2BlTXOd
Commentary
Drug resistance-associated substitutions identified in HCV genes
Last Updated: 2017-11-24
By Marilynn Larkin
NEW YORK (Reuters Health) - In patients who fail direct-acting antiviral therapy for hepatitis C virus (HCV) infection, resistance-associated substitutions (RASs) vary by HCV genotype and subtype and with different classes of drugs - a finding that might be used to select salvage therapies, researchers suggest."Little is known about (genetic) substitutions that mediate resistance of HCV to direct-acting antivirals, due to the small number of patients with treatment failure in approval studies," note Dr. Christoph Sarrazin of the University of Frankfurt, in Germany, and colleagues.
To investigate, the team analyzed samples from patients who had HCV infection with genotypes 1 to 6 for RASs in HCV genes (NS3, NS5A, NS5B) that are targeted by direct-acting antivirals.
Continue to article - http://ift.tt/2zoyhiW
Thus Article Drug resistance-associated substitutions identified in HCV genes
That's an article Drug resistance-associated substitutions identified in HCV genes This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Drug resistance-associated substitutions identified in HCV genes with the link address https://theleknews.blogspot.com/2017/11/drug-resistance-associated.html
0 Response to "Drug resistance-associated substitutions identified in HCV genes"
Post a Comment